Analysts Offer Insights on Healthcare Companies: Novan (NOVN), Pelthos Therapeutics (PTHS) and Scholar Rock Holding (SRRK)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Novan (NOVN – Research Report), Pelthos Therapeutics (PTHS – Research Report) and Scholar Rock Holding (SRRK – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pelthos Therapeutics (PTHS)
In a report released today, James Molloy from Alliance Global Partners reiterated a Buy rating on Pelthos Therapeutics, with a price target of $75.00. The company’s shares closed last Friday at $22.99.
According to TipRanks.com, Molloy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Pelthos Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $59.80, implying a 135.6% upside from current levels. In a report issued on December 3, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $60.00 price target.
Scholar Rock Holding (SRRK)
In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Scholar Rock Holding. The company’s shares closed last Friday at $46.87, close to its 52-week high of $46.98.
According to TipRanks.com, Devarakonda is a 5-star analyst with an average return of
Scholar Rock Holding has an analyst consensus of Strong Buy, with a price target consensus of $46.78.
